Aurora Therapeutics' first target is the rare inherited disease phenylketonuria, also known as PKU. Here at MIT Technology Review we’ve been writing about the gene-editing technology CRISPR since 2013 ...
The biotech startup Inscripta is attempting to “democratize” CRISPR by offering it to select researchers at no cost, according to Fortune. Here are four things to know about the startup’s business ...
Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The funding has enabled CRISPR co-inventor Jennifer Doudna, Ph.D., and baby KJ scientist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results